Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 4 | 2024 | 22 | 1.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 139 | 1.800 |
Why?
|
| Hypoglycemia | 1 | 2023 | 4 | 0.860 |
Why?
|
| Glycated Hemoglobin A | 2 | 2018 | 24 | 0.740 |
Why?
|
| Blood Glucose | 2 | 2018 | 107 | 0.710 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2019 | 2 | 0.660 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 10 | 0.650 |
Why?
|
| Insulin | 1 | 2019 | 73 | 0.640 |
Why?
|
| Albuminuria | 1 | 2018 | 20 | 0.610 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 146 | 0.380 |
Why?
|
| Adult | 7 | 2024 | 5913 | 0.330 |
Why?
|
| Humans | 10 | 2024 | 14537 | 0.260 |
Why?
|
| South Africa | 8 | 2024 | 7596 | 0.250 |
Why?
|
| Receptors, Calcitriol | 1 | 2024 | 4 | 0.240 |
Why?
|
| Vitamin D | 1 | 2024 | 41 | 0.230 |
Why?
|
| HIV Infections | 2 | 2024 | 5097 | 0.230 |
Why?
|
| Middle Aged | 4 | 2024 | 3601 | 0.230 |
Why?
|
| Male | 6 | 2024 | 6754 | 0.220 |
Why?
|
| Epidemics | 1 | 2024 | 65 | 0.210 |
Why?
|
| Health Care Sector | 1 | 2023 | 8 | 0.210 |
Why?
|
| Genotype | 1 | 2024 | 442 | 0.210 |
Why?
|
| Diet, Ketogenic | 1 | 2022 | 1 | 0.200 |
Why?
|
| Ketosis | 1 | 2022 | 2 | 0.200 |
Why?
|
| Health Care Costs | 1 | 2023 | 115 | 0.200 |
Why?
|
| Zinc Transporter 8 | 1 | 2021 | 2 | 0.190 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 6 | 0.190 |
Why?
|
| Obesity | 2 | 2024 | 367 | 0.190 |
Why?
|
| Autoantibodies | 1 | 2021 | 49 | 0.190 |
Why?
|
| Telemedicine | 1 | 2020 | 25 | 0.180 |
Why?
|
| Female | 5 | 2024 | 9103 | 0.180 |
Why?
|
| Disease Management | 1 | 2020 | 74 | 0.170 |
Why?
|
| Biomarkers | 1 | 2021 | 327 | 0.170 |
Why?
|
| Retrospective Studies | 1 | 2023 | 799 | 0.170 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2016 | 17 | 0.170 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 16 | 0.160 |
Why?
|
| Medical Audit | 1 | 2019 | 26 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 156 | 0.160 |
Why?
|
| Odds Ratio | 1 | 2019 | 133 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 80 | 0.160 |
Why?
|
| Glycemic Index | 1 | 2018 | 2 | 0.160 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 12 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 253 | 0.150 |
Why?
|
| Time Factors | 1 | 2019 | 507 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 1422 | 0.140 |
Why?
|
| Treatment Outcome | 1 | 2019 | 889 | 0.130 |
Why?
|
| Aged | 2 | 2018 | 1740 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 656 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2019 | 1160 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2015 | 54 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 91 | 0.120 |
Why?
|
| Health Facility Closure | 1 | 2014 | 5 | 0.120 |
Why?
|
| Hospital Units | 1 | 2014 | 7 | 0.120 |
Why?
|
| Mass Screening | 1 | 2016 | 245 | 0.120 |
Why?
|
| Hospitals, Public | 1 | 2014 | 45 | 0.110 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2016 | 324 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2024 | 480 | 0.090 |
Why?
|
| Prevalence | 3 | 2021 | 1192 | 0.080 |
Why?
|
| Prognosis | 2 | 2021 | 199 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 188 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2024 | 22 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 176 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 198 | 0.050 |
Why?
|
| Adolescent | 2 | 2024 | 2985 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2022 | 1 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2022 | 4 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2022 | 18 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 40 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 179 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 1475 | 0.050 |
Why?
|
| Middle East | 1 | 2020 | 8 | 0.050 |
Why?
|
| Europe | 1 | 2020 | 56 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 370 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 188 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 376 | 0.040 |
Why?
|
| Young Adult | 1 | 2024 | 2498 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 43 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2015 | 225 | 0.030 |
Why?
|
| Private Sector | 1 | 2014 | 45 | 0.030 |
Why?
|